durvalumab,paclitaxel
astrazeneca,bms
[]
shocked to see swog1815 is negative. adding abraxane to gem/cis did not improve os or orr.
orr: 31% vs. 26% orr with topaz-1. gem/cis + durvalumab remains king! #gi23 #ascogi23 
GI #Oncologist @ClevelandClinic | @USNews contributor | Tweets my own